Core Insights - Shanghai Jieshi Medical Technology Co., Ltd. successfully completed a Series B financing round led by Yunsheng Investment, with Xingliang Investment participating, to accelerate the commercialization of core products, new product development, and market expansion [1] Company Overview - Jieshi Medical was established in January 2013 in Zhangjiang Medical Device Industrial Base, focusing on solutions for retinal diseases and vision restoration, with a product matrix that includes several products approved for sale in China [1] - The company has developed a range of products including Jieshi® perfluoropropane gas, Zhongshui® perfluorohexane for ophthalmic surgery, and various single-use ophthalmic puncture systems, among others [1] Product Innovations - The Jieshi® perfluoropropane gas, which received NMPA Class III certification in February this year, is the first domestically approved long-acting filling gas for ophthalmic use, specifically designed for vitreoretinal surgery [1][2] - The product is characterized by its high purity (99%) and unique design that addresses the high costs and infection risks associated with imported products, thus improving patient treatment timelines [2] - The Zhongshui® perfluorohexane is noted as the only second-generation heavy water in China, offering higher purity (≥ 99.98%) and improved safety features compared to first-generation products [2] Market Potential - The demand for ophthalmic medical devices is expected to rise due to aging populations and economic development, positioning Jieshi Medical as a key player in the domestic market [3] - The company aims to fill gaps in the domestic market with innovative products, leveraging its experienced team to address clinical pain points through product development [3][4] - The overall market for ophthalmic medical devices in China is anticipated to improve as more innovative companies like Jieshi Medical emerge, enhancing the domestic replacement rate in this sector [4]